(NasdaqGM: MSON), a medical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for wound debridement, spine surgery, cosmetic surgery, neurosurgery, laparoscopic surgery and other surgical applications has entered into a new, three-year, exclusive distribution agreement with B. Braun Medical, S.A. for the distribution of the SonaStar@ Ultrasonic Surgical Aspirator and the BoneScalpelT Ultrasonic Bone Cutter. The agreement provides B. Braun with the rights to sell throughout Ecuador. Included in the agreement are annual minimum purchase requirements. Product training and registration are complete; open market sales have commenced.
B. Braun is well-entrenched in the fields of spine surgery and neurosurgery with a long-standing reputation for successfully introducing state-of-the-art technology to the Ecuadorian market.
Their commitment to product service and physician education is consistent with the Company's core values.
The SonaStar is used by neurosurgeons and general surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels. OsteoSculptT bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.
The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument without the danger associated with rotary sharps.
"We are very pleased to add B. Braun as a business partner, adding another top-notch company to our broad-based Latin American distribution team. Their reputation for successfully introducing advanced medical devices is well known," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "We are particularly pleased that they will be selling two of our key products throughout Ecuador." About Misonix Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
Safe Harbor Statement With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made.
These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
Investor Relations Contacts Misonix Contact: Lytham Partners, LLC Richard Zaremba Robert Blum, Joe Dorame, Joe Diaz 631-694-9555 602-889-9700 firstname.lastname@example.org email@example.com SOURCE Misonix, Inc.
-0- 03/29/2012 /Web Site: http://www.misonix.com (NASDAQ-NMS:MSON) / CO: Misonix, Inc.; B. Braun Medical, S.A.
ST: New York Ecuador IN: FIN HEA MTC MEQ SU: LIC PRN -- LA78434 -- 0000 03/29/2012 11:30:00 EDT http://www.prnewswire.c